Sign Out
Olopatadine: In vitro studies have shown that olopatadine does not inhibit metabolic reactions which involve cytochrome P-450 isoenzymes (1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4). Olopatadine is moderately bound to plasma proteins (approximately 55%). These results indicate that olopatadine is unlikely to result in interactions with other concomitantly administered medications.
Mometasone Furoate: Studies have shown that mometasone furoate is primarily and extensively metabolized in the liver of all species investigated and undergoes extensive metabolism to multiple metabolites with no major metabolites detected in plasma. Mometasone furoate is metabolized by CYP3A4.
Co-treatment with CYP3A inhibitors is expected to increase the risk of systemic corticosteroid side-effects. The combination should be avoided unless the benefit outweighs the increased risk of systemic corticosteroid side-effects, in which case patients should be monitored for systemic corticosteroid side-effects.
Concurrent use of OLOPATADINE AND MOMETASONE (RYALTRIS) with alcohol or other central nervous system depressants should be avoided because additional reductions in alertness and additional impairment of central nervous system performance may occur.
Drug-Drug Interactions: The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated). (See Table 2.)
Click on icon to see table/diagram/imageDrug-Food Interactions: Interactions with food have not been established.
Drug-Herb Interactions: Interactions with herbal products have not been established.
Drug-Laboratory Test Interactions: Interactions with laboratory tests have not been established.
